Recombinant human interleukin-10 in patients with chronic myelomonocytic leukemia

Ann Hematol. 2014 Oct;93(10):1775-6. doi: 10.1007/s00277-014-2012-5. Epub 2014 Jan 18.

Authors

Sophie Pöchlauer¹, Eva Jäger, Ulrich Jäger, Klaus Geissler

Affiliation

¹ 5th Department of Internal Medicine-Oncology/Hematology, Krankenhaus Hietzing, Wolkersbergenstraße 1, 1130, Vienna, Austria.

PMID: 24441916
DOI: 10.1007/s00277-014-2012-5

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

B7-2 Antigen / biosynthesis
Down-Regulation
Drug Evaluation
Drug Screening Assays, Antitumor
Female
Humans
Interleukin-10 / genetics
Interleukin-10 / pharmacology
Interleukin-10 / therapeutic use*
Leukemia, Myelomonocytic, Chronic / drug therapy*
Leukemia, Myelomonocytic, Chronic / pathology
Male
Monocytes / drug effects
Monocytes / metabolism
Muramidase / blood
Neoplasm Proteins / blood
Pilot Projects
Recombinant Proteins / pharmacology
Recombinant Proteins / therapeutic use
Skin / pathology
Tumor Cells, Cultured

Substances

B7-2 Antigen
IL10 protein, human
Neoplasm Proteins
Recombinant Proteins
Interleukin-10
Muramidase